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Andrew R. Gennery | University of Newcastle upon Tyne
In this issue of Blood, Haddad and colleagues on behalf of the Primary Immune
Deficiency Treatment Consortium report retrospective outcome data on
hematopoietic stem cell transplantation (HSCT) for 662 patients with severe
combined immunodeficiency (SCID) treated between 1982 and 2012 in 33
North American institutions.1
Inborn errors of immunity are genetic
diseases predisposing affected individ-
uals to an increased risk of infection,
autoimmunity, or malignancy. The most
severe of these disorders, SCID, charac-
terized by absent or dysfunctional T lym-
phocytes affecting cellular and humoral
adaptive immunity, is life threatening when
recognized too late. Contingent on the
genetic defect, B lymphocytes and natural
killer cells may be present or absent. Since
the first HSCT for SCID was performed
50 years ago, discussion among special-
ists caring for these patients has continued
over the best approach to treatment.
Following that first report, much has been
learned about different SCID genotypes,
clinical and immunophenotypes, and nat-
ural history. In parallel, transplant tech-
niques and approaches have evolved so
that today, survival in this group of in-
fants approaches 90% in recent series.2,3
However, debate around the best alter-
native donor, use of conditioning, and
optimum early biomarkers indicating re-
quirement for a further transplant pro-
cedure continues. Problems in resolving
the issues include rarity of the disease,
and limited experience of any 1 center in
treating these patients. Furthermore, his-
toric series have analyzed SCID on phe-
notypic presentation, whereas genotype,
rather than phenotype, may be more
important.4,5 In this issue, Haddad and
colleagues analyze outcome of 662 SCID
patients treated between 1982 and 2012
in 33 North American institutions. This is
one of the largest multicenter studies to
date, and for the first time in such a cohort,
outcome has been documented accord-
ing to genotype. As with any such study, a
number of limitations are apparent: over
the timescale of 30 years, there have been
tremendous improvements in approach
to diagnosis of SCID and all aspects of
HSCT. The multicenter approach means it
is inevitable that data are missing, and not
all patients will be adequately accounted
for. Centers may use different transplant
techniques and specialize in treating specific
genetic defects. Furthermore, genetic in-
formation was incomplete and only avail-
able in 58% of patients. Nevertheless, given
the rigorous eligibility criteria for the study,
important information can be gleaned.
First, the superiority of matched sibling
donors corroborates results from pre-
vious studies. However, there were no
significant differences in survival when
comparing other donor types, which
confirms observations from the European
Inborn Errors Working Party in their most
recent epoch analysis, and others.3,6 This
information will be useful for resource-limited
centers for which use of unrelated donors
may be precluded. Fine detail about
differences in T-lymphocyte depletion
methodswas not available, and in themodern
era, nuances in technique may improve
survival further. Second, the importance of
transplantation before infection is present
is now well established,2 but the current
study noted outcome differences in age
at transplant in those with infection, with
patients .3.5 months of age at transplant
having a worse outcome than those trans-
planted ,3.5 months of age. The reasons
for this are not clear andmay includemore
advanced end-organ damage in the older
group, but emphasize that SCID is amedical
emergency, and early diagnosis through
newborn screening andearly transplant lead
to best outcomes.7
Third, this study found no difference in
transplant outcome between patients
with “classical” or atypical/leaky SCID, in
contradistinction to the results reported
by the European group.3 The reasons for
this difference in outcome are not obvi-
ous, and detailed analysis of the 2 groups
may be required to explain this difference.
Fourth, similar to the European group, this
study found no survival difference between
those receiving chemotherapy condition-
ing and those receiving only immuno-
suppression or no preparative regimen.
Although at first reading this might argue
that either approach is valid, the present
study also confirmed observations that a
pretransplant preparative regimen is as-
sociated with durable engraftment,8 the
primary goal of treatment of these pa-
tients. Thus, this study adds to the
growing body of evidence that suggests
best outcomes in terms of graft durability
and immune reconstitution occur when a
chemotherapy-based preparative regi-
men is administered before allograft
infusion. However, the importance of
detailed analysis based on genotype is
clearly demonstrated by the finding that
survival of patients with radiosensitive
SCID (Artemis deficiency) was worse than
those of RAG-deficient SCID, despite
similar immunotypes, and not demon-
strated in a previous report.9 Importantly,
the increased mortality in the radiosen-
sitive SCID group was not due to infec-
tious causes, suggesting that the interplay
of chemotherapy and the systemic nature
of the radiosensitive defect may play an
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important role in outcome, so although
conditioning may be required to achieve
enduring immunity, safer, less toxic meth-
ods of achieving robust stem cell engraft-
ment are required.10
Finally and importantly, this study leads
us closer to identifying failing grafts, to
enable early and effective intervention.
It is difficult to identify in which patients
immune reconstitution is likely to be
suboptimal, and therefore, in whom an
early decision to boost or retransplant
should be taken, important because early
intervention is more likely to be suc-
cessful. However, additional procedures
should be avoided in those patients who
do not require them. This large cohort
study confirms and connects observa-
tions from a number of previous small
studies, namely that durable T-lymphocyte
reconstitution associates with better sur-
vival; good T-lymphocyte reconstitution at
1 to 2 years post-HSCT associates with
better T-lymphocyte long-term immune
reconstitution, and high T-lymphocyte re-
ceptor excision (TREC) circle counts,markers
of thymopoiesis, at 6 months associate with
robust long-term T-lymphocyte reconstitution
(see figure).
This study and other large cohort studies
of SCID patients strongly emphasize
the critical importance of multicenter
collaboration and long-term follow-
up of these rare patients in experienced
centers collecting good-quality data;
without careful analysis of the minutiae of
immune reconstitution according to pre-
parative conditioning regimen and ge-
notype over 30 years, this study would
have no added value over previous
studies. Over the years, small pieces of
the jigsaw puzzle have been pieced to-
gether, so we now have a much clearer
picture of how our treatments impact our
patients in the short and long term. The
next steps will be to gather good-quality
data on the impact of our treatment on
life quality, and on very long-term out-
comes. This study helps lay the founda-
tion for those future analyses.
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(A) Longitudinal increased numbers of naive T lymphocytes are associated with chemotherapy conditioning.
Adapted from Abd Hamid et al.4 (B) Overall longterm survival is associated with increased numbers of naive
T lymphocytes. Panel (B) has been adapted from Figure 3A in the article by Haddad et al that begins on page 1737.
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AHR: leukemic
countermeasure against
NK cells
Nicolas Dulphy | Universite´ Paris Diderot
In this issue of Blood, Scoville et al report an original mechanism by which the
aryl hydrocarbon receptor (AHR) allows acute myeloid leukemia (AML) to
escape the natural killer (NK) cell–mediated antitumor immunosurveillance
by increasing expression of microRNA (miR)–29b, thereby inhibiting NK-cell
maturation and function.1
The seminal work by Ruggeri et al dem-
onstrated that NK cells are critical ef-
fector cells in graft-versus-leukemia in
AML after hematopoietic stem cell
transplantation.2 AML patients at diagno-
sis show deeply impaired NK-cell function
against leukemia, with decreased capacity
to release cytokines, such as interferon g,
and reducedcytotoxicitywith lowexpression
of intracellular cytolytic enzymes (perforin,
granzymes). In that context, NK-cell de-
fects are often associated with a specific
AML transcription program,3 emphasizing
the intimate relationship taking place
between both cell types during leukemo-
genesis. Mechanisms by which AML in-
duces such profound and sustained NK
cell defects are still largely unknown.4
Consequently, there is a quest to de-
velop strategies to reactivate antitumor
NK-cell function in support of patients’
treatment at diagnosis or after com-
plete remission.
Scoville et al identified AHR as a key
factor in the NK cell/leukemia cross talk
resulting in the inhibition of the NK-cell
maturation and function, and in inducing re-
sistance of AML blasts to NK-cell-mediated
killing (see figure). Soluble ligands secreted
by AML cells, which remain unidentified,
trigger the AHR pathway in NK cells, which
in turn increases the transcription of miR-
29b and thereby inhibits NK-cell matura-
tion, with a blockade at an immature and
poorly functional differentiation stage. The
importance of miR-29b in regulating NK-
cell maturation and function in the context
of AML, previously described in mouse
models by the authors,5 was herein con-
firmed in humans. AHR appears to be a
direct regulator of miR-29b transcription
through its binding onto the miR-29a/b1
promoter, suggesting theAHRpathway is a
major mechanism by which AML dampens
antitumor immunity. Treatment with an AHR
antagonist of NK cells cocultured with AML
could abrogate increased miR-29b expres-
sion and restore NK-cell maturation and
function. Interestingly, AHR was also in-
volved in AML survival and its resistance to
NK-cell cytotoxicity.
There is growing interest in the role of
AHR in the emergence and progression
of cancer. Notably, AHR has been asso-
ciated with the regulation of numerous
biological processes important in tumori-
genesis, including proliferation, migration,
and inflammatory signaling.6 In addition,
AHR expression is increased in tumors
relative to healthy surrounding tissues.
However, AHR function varies according
to the cell where it is expressed. Together
with the wide diversity of endogenous
and exogenous AHR ligands, it explains
the difficulty in addressing the role of this
transcription factor in cancer. Scoville
et al showed that the AHR pathway could
not only promote intrinsic capacities of
resistance and survival of tumor cells, but
also generate an inhibiting microenvi-
ronment preventing the antitumor im-
mune response. Importantly, the AHR/
miR-29b pathway did not directly inhibit
NK-cell function when AHR was triggered
in mature NK cells but impaired the
upstream development of the NK-cell
precursors. This observation is reminis-
cent of previous data by Roeven et al
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AML can escape NK-cell antitumor responses by stimulating the AHR pathway both in NK and AML cells, which will
inhibit NK cell maturation and function and promote AML cell survival.
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